| 1: J
Neuropathol Exp Neurol. 2006 Jun;65(6):549-61. |
|
-
High-resolution array-based comparative genomic
hybridization of medulloblastomas and supratentorial primitive
neuroectodermal tumors.
McCabe
MG, Ichimura
K, Liu
L, Plant
K, Backlund
LM, Pearson
DM, Collins
VP.
From the Department of Pathology (MGM, KI, LL, KP, DMP, VPC); University of
Cambridge, Division of Molecular Histopathology, Cambridge, U.K.; and
Department of Oncology Pathology (LMB), Karolinska Institute, Stockholm,
Sweden.
Medulloblastomas and supratentorial primitive neuroectodermal tumors are
aggressive childhood tumors. We report our findings using array comparative
genomic hybridization (CGH) on a whole-genome BAC/PAC/cosmid array with a
median clone separation of 0.97 Mb to study 34 medulloblastomas and 7
supratentorial primitive neuroectodermal tumors. Array CGH allowed
identification and mapping of numerous novel, small regions of copy number
change to genomic sequence in addition to the large regions already known
from previous studies. Novel amplifications were identified, some
encompassing oncogenes MYCL1, PDGFRA, KIT, and MYB not previously reported
to show amplification in these tumors. In addition, one supratentorial
primitive neuroectodermal tumor had lost both copies of the tumor-suppressor
genes CDKN2A and CDKN2B. Ten medulloblastomas had findings suggestive of
isochromosome 17q. In contrast to previous reports using conventional CGH,
array CGH identified 3 distinct breakpoints in these cases: Ch 17:
17940393-19251679 (17p11.2, n = 6), Ch 17: 20111990-23308272
(17p11.2-17q11.2, n = 4), and Ch 17: 38425359-39091575 (17q21.31, n = 1).
Significant differences were found in the patterns of copy number change
between medulloblastomas and supratentorial primitive neuroectodermal
tumors, providing further evidence that these tumors are genetically
distinct despite their morphologic and behavioral similarities.
PMID: 16783165 [PubMed - in process]
-
| 2: J
Neuropathol Exp Neurol. 2006 Jun;65(6):529-39. |
|
-
'Pseudopalisading' necrosis in glioblastoma: a familiar
morphologic feature that links vascular pathology, hypoxia, and angiogenesis.
Rong
Y, Durden
DL, Van
Meir EG, Brat
DJ.
From the Departments of Pathology and Laboratory Medicine (YR, DJB),
Pediatrics (DLD), Hematology/Oncology (DLD, EGVM), and Neurosurgery (EGVM),
Winship Cancer Institute, Emory University School of Medicine, Atlanta,
Georgia.
Glioblastoma (GBM) is a highly malignant, rapidly progressive astrocytoma
that is distinguished pathologically from lower grade tumors by necrosis and
microvascular hyperplasia. Necrotic foci are typically surrounded by "pseudopalisading"
cells-a configuration that is relatively unique to malignant gliomas and has
long been recognized as an ominous prognostic feature. Precise mechanisms
that relate morphology to biologic behavior have not been described. Recent
investigations have demonstrated that pseudopalisades are severely hypoxic,
overexpress hypoxia-inducible factor (HIF-1), and secrete proangiogenic
factors such as VEGF and IL-8. Thus, the microvascular hyperplasia in GBM
that provides a new vasculature and promotes peripheral tumor expansion is
tightly linked with the emergence of pseudopalisades. Both pathologic
observations and experimental evidence have indicated that the development
of hypoxia and necrosis within astrocytomas could arise secondary to vaso-occlusion
and intravascular thrombosis. This emerging model suggests that
pseudopalisades represent a wave of tumor cells actively migrating away from
central hypoxia that arises after a vascular insult. Experimental glioma
models have shown that endothelial apoptosis, perhaps resulting from
angiopoetin-2, initiates vascular pathology, whereas observations in human
tumors have clearly demonstrated that intravascular thrombosis develops with
high frequency in the transition to GBM. Tissue factor, the main cellular
initiator of thrombosis, is dramatically upregulated in response to PTEN
loss and hypoxia in human GBM and could promote a prothrombotic environment
that precipitates these events. A prothrombotic environment also activates
the family of protease activated receptors (PARs) on tumor cells, which are
G-protein-coupled and enhance invasive and proangiogenic properties. Vaso-occlusive
and prothrombotic mechanisms in GBM could readily explain the presence of
pseudopalisading necrosis in tissue sections, the rapid peripheral expansion
on neuroimaging, and the dramatic shift to an accelerated rate of clinical
progression resulting from hypoxia-induced angiogenesis.
PMID: 16783163 [PubMed - in process]>>>
-
| 3: Neuroradiology.
2006 Jun 20; [Epub ahead of print] |
|
-
The contribution of diffusion-weighted MR imaging to
distinguishing typical from atypical meningiomas.
Hakyemez
B, Yildirim
N, Gokalp
G, Erdogan
C, Parlak
M.
Department of Radiology, Uludag University School of Medicine, Gorukle,
Bursa, Turkey.
INTRODUCTION: Atypical/malignant meningiomas recur more frequently then
typical meningiomas. In this study, the contribution of diffusion-weighted
MR imaging to the differentiation of atypical/malignant and typical
meningiomas and to the determination of histological subtypes of typical
meningiomas was investigated. METHODS: The study was performed prospectively
on 39 patients. The signal intensity of the lesions was evaluated on trace
and apparent diffusion coefficient (ADC) images. ADC values were measured in
the lesions and peritumoral edema. Student's t-test was used for statistical
analysis. P<0.05 was considered statistically significant. RESULTS: Mean
ADC values in atypical/malignant and typical meningiomas were 0.75+/-0.21
and 1.17+/-0.21, respectively. Mean ADC values for subtypes of typical
meningiomas were as follows: meningothelial, 1.09+/-0.20; transitional,
1.19+/-0.07; fibroblastic, 1.29+/-0.28; and angiomatous, 1.48+/-0.10. Normal
white matter was 0.91+/-0.10. ADC values of typical meningiomas and
atypical/malignant meningiomas significantly differed (P<0.001). However,
the difference between peritumoral edema ADC values was not significant
(P>0.05). Furthermore, the difference between the subtypes of typical
meningiomas and atypical/malignant meningiomas was significant (P<0.001).
CONCLUSION: Diffusion-weighted MR imaging findings of atypical/malignant
meningiomas and typical meningiomas differ. Atypical/malignant meningiomas
have lower intratumoral ADC values than typical meningiomas. Mean ADC values
for peritumoral edema do not differ between typical and atypical meningiomas.
PMID: 16786348 [PubMed - as supplied by publisher]>>>
-
| 4: Neurosurg
Clin N Am. 2006 Apr;17(2):149-67. |
|
-
Less common indications for stereotactic radiosurgery or
fractionated radiotherapy for patients with benign brain tumors.
Knisely
JP, Linskey
ME.
Department of Therapeutic Radiology, Yale University School of Medicine,
Hunter Radiation Therapy Center, PO Box 208040, New Haven, CT 06520-8040,
USA.
PMID: 16793507 [PubMed - in process]>>>
-
| 5: Neurosurg
Clin N Am. 2006 Apr;17(2):143-8. |
|
-
Role of radiation therapy and radiosurgery in the
management of craniopharyngiomas.
Suh
JH, Gupta
N.
Brain Tumor Institute, Department of Radiation Oncology, T28, Cleveland
Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
PMID: 16793506 [PubMed - in process]
-
| 6: Neurosurg
Clin N Am. 2006 Apr;17(2):111-20. |
|
-
Meningioma.
Goldsmith
B, McDermott
MW.
Department of Neurological Surgery, University of California, San Francisco,
400 Parnassus, 8th Floor, San Francisco, CA 94143, USA.
PMID: 16793503 [PubMed - in process]
| 7: Surg Neurol. 2006 Jul;66(1):37-44. |
|
-
Tuberculum sellae meningiomas: functional outcome in a
consecutive series treated microsurgically.
Bassiouni
H, Asgari
S, Stolke
D.
Department of Neurosurgery, University Hospital Essen, Essen, Germany.
OBJECTIVE: The objective of this study was to analyze a series of patients
harboring a tuberculum sellae meningioma with regard to clinical
presentation and long-term functional outcome. METHODS: Data in a
consecutive series of 62 patients harboring a tuberculum sellae meningioma
treated microsurgically between 1990 and 2003 were retrospectively reviewed.
RESULTS: The mean age of the 46 women and 16 men enrolled in the study was
53 years (range = 29-81 years). The presenting symptom was visual compromise
in 87.1% of the patients, and examination revealed decreased visual acuity
in 79% and impaired visual fields in 64.5% of the patients. In addition,
14.5% of the patients had preoperative hormonal abnormalities. Simpson
grades I and II resections, usually via a pterional approach, were achieved
in 90.3% of the patients. Postoperatively, vision improved in 53.2%,
remained unchanged in 29.8%, and deteriorated in 17.0% of the patients. The
intraoperative finding predicting an unfavorable visual outcome was a thin
atrophic optic nerve, encasement of the nerve, or tumor adhesion to its
undersurface. Of the patients, 12.9% required permanent postoperative
hormonal replacement. After a mean follow-up period of 6.0 years (range = 18
months-14 years), 88.7% of the patients resumed normal life activity and 2
recurrent tumors were observed (3.2%) and reoperated. CONCLUSIONS:
Preoperative magnetic resonance imaging provides reliable information with
regard to dislocation of critical vascular structures. However, the
relationship between optic nerves and tumors (eg, adhesion and encasement)
affected postoperative results and can only be fully appreciated during
microsurgery. Visual outcome may be improved by preserving the
microvasculature supplying the optic apparatus.
PMID: 16793435 [PubMed - in process]
-
-
| 8: J
Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:439-46. |
|
Craniopharyngioma radiotherapy: endocrine and cognitive
effects.
Merchant
TE.
Division of Radiation Oncology, St. Jude Children's Research Hospital, 332
North Lauderdale Street, Memphis, TN 38104, USA. thomas.merchant@stjude.org
Potential existing and treatment associated deficits in neurological,
endocrine and cognitive function influence treatment decisions and the use
of radiation therapy in children with craniopharyngioma. Neurological
deficits are uncommon after radiation therapy, endocrine deficiencies are
typically present prior to treatment, and cognitive effects depend on a wide
range of clinical and treatment-related factors in addition to radiation
dosimetry. Early and accurate evaluation of these functions should be
considered for all patients to provide parents and caregivers with the
information necessary to plan intervention and mitigate the consequences of
tumor and treatment.
Publication Types:
PMID: 16700322 [PubMed - indexed for MEDLINE]>>>
-
| 9: Radiology.
2006 May;239(2):506-13. |
|
-
Supratentorial low-grade glioma resectability:
statistical predictive analysis based on anatomic MR features and tumor
characteristics.
Talos
IF, Zou
KH, Ohno-Machado
L, Bhagwat
JG, Kikinis
R, Black
PM, Jolesz
FA.
Department of Radiology, Brigham and Women's Hospital, Harvard Medical
School, Boston, MA, USA.
PURPOSE: To retrospectively assess the main variables that affect the
complete magnetic resonance (MR) imaging-guided resection of supratentorial
low-grade gliomas. MATERIALS AND METHODS: Institutional review board
approval was obtained for this retrospective HIPAA-compliant study, with the
requirement for informed consent waived. Data from 101 patients (61 men, 40
women; mean age, 39 years; age range, 18-72 years) who had nonenhancing
supratentorial mass lesions that were histopathologically diagnosed as
low-grade (World Health Organization grade II) gliomas and consecutively
underwent surgery with intraoperative MR imaging guidance were analyzed.
There were 21 low-grade astrocytomas, 64 oligodendrogliomas, and 16 mixed
oligoastrocytomas. Initial and residual tumor volumes were measured on
intraoperative T2-weighted MR images and three-dimensional spoiled
gradient-echo MR images. The anatomic relationships between the tumor and
eloquent cortical and/or subcortical regions and the influence of these
relationships on the extent of resection were analyzed on the basis of
preoperative MR imaging findings. Summary measures, univariate Fisher exact
test and t test, and multivariate logistic regression analyses were
performed. RESULTS: Tumor volume ranged from 2.7-231.0 mL. Univariate
analyses revealed the following tumor characteristics to be significant
predictive variables of incomplete tumor resection: diffuse tumor margin on
T2-weighted MR images, oligodendroglioma or oligoastrocytoma histopathologic
type, and large tumor volume (P < .05 for all). Tumor involvement of the
following structures was associated with incomplete resection: corpus
callosum, corticospinal tract, insular lobe, middle cerebral artery, motor
cortex, optic radiation, visual cortex, and basal ganglia (P < .05 for
all). Multivariate analyses revealed that incomplete tumor resection was due
to tumor involvement of the corticospinal tract (P < .01), large tumor
volume (P < .01), and oligodendroglioma histopathologic type (P = .02).
CONCLUSION: The main variables associated with incomplete tumor resection in
101 patients were identified by using statistical predictive analyses. (c)
RSNA, 2006.
PMID: 16641355 [PubMed - indexed for MEDLINE]>>>
-
| 10: J Neurosurg. 2006 Apr;104(4):618-20. |
|
Possibility of using laser spectroscopy for the
intraoperative detection of nonfluorescing brain tumors and the boundaries
of brain tumor infiltrates. Technical note.
Utsuki
S, Oka
H, Sato
S, Suzuki
S, Shimizu
S, Tanaka
S, Fujii
K.
Department of Neurosurgery, Kitasato University School of Medicine,
Sagamihara, Kanagawa, Japan. utsuki@med.kitasato-u.ac.jp
The response of nonfluorescing infiltrating tumors that had been exposed to
5-aminolevulinic acid and irradiated using a laser at a wavelength of 405 nm
was analyzed intraoperatively using spectroscopy. Histological analyses
demonstrated that neoplastic cells were present in the tissue region that
displayed a peak at 636 nm, whereas no neoplastic cells were present in the
region that exhibited only the excitation light peak. The authors conclude
that the intraoperative use of laser spectroscopy can allow the diagnosis of
infiltrating tumor and the detection of boundaries of the infiltrate when
standard fluorescence techniques fail.
PMID: 16619668 [PubMed - indexed for MEDLINE]>>>
-
| 11: J Neurosurg. 2006 Apr;104(4):542-50. |
|
The impact of genotype on outcome in oligodendroglioma:
validation of the loss of chromosome arm 1p as an important factor in
clinical decision making.
Kanner
AA, Staugaitis
SM, Castilla
EA, Chernova
O, Prayson
RA, Vogelbaum
MA, Stevens
G, Peereboom
D, Suh
J, Lee
SY, Tubbs
RR, Barnett
GH.
The Brain Tumor Institute, The Cleveland Clinic Taussig Cancer Center, The
Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
OBJECT: Oligodendrogliomas are rare primary brain tumors. They comprise
approximately 5 to 33% of all glial tumors but differ from astrocytomas by
being associated with a more favorable prognosis, making their correct
identification important. Allelic loss of chromosome arms 1p and 19q is
found in a substantial subpopulation of tumors with an oligodendroglioma
phenotype. Anaplastic oligodendrogliomas with allelic loss of 1p have been
associated with chemosensitivity and a longer patient survival period.
METHODS: Oligodendroglial neoplasms were studied using fluorescence in situ
hybridization of formalin-fixed, paraffin-embedded tissue specimens;
reference and target probe sets were used to map the telomeric regions of 1p
and 19q. The results were correlated with the clinical characteristics of
patients treated at our institution between 1993 and 2003. Data obtained in
96 patients were analyzed. This included 63 patients (65.6%) with World
Health Organization (WHO) Grade II oligodendroglioma, 22 (23%) with Grade
III oligodendroglioma, and 11 (11.4%) with mixed oligoastrocytoma. Analysis
of 1p in patients with pure oligodendroglioma revealed a loss of 1p in 42
patients (49.4%). In 46 of these patients 19q was lost and in 70 (82.3%)
there was concordance for combined loss or retention of both 1p and 19q (p
< 0.0001). Patients with oligodendroglioma in whom a loss of 1p was
present fared significantly better, and this outcome was unrelated to the
treatment modality or WHO grade, compared with patients in whom 1p was
intact (p < 0.05). CONCLUSIONS: To the authors' knowledge, this study
includes the largest published series of WHO Grade II oligodendroglioma and
1p analysis. The results suggest that the association between long-term
survival and 1p loss in oligodendroglioma is unrelated to treatment. The
authors of further prospective studies may better determine the true value
of the allelic loss of 1p and its implication for clinical decision making.
PMID: 16619658 [PubMed - indexed for MEDLINE]>>>
-
| 12: J Neurosurg. 2006 Apr;104(4):537-41. |
|
Modification of glucose metabolism in brain tumors by
using cervical spinal cord stimulation.
Clavo
B, Robaina
F, Montz
R, Domper
M, Carames
MA, Morera
J, Pinar
B, Hernandez
MA, Santullano
V, Carreras
JL.
Department of Radiation Oncology-Research, Dr. Negrin University Hospital,
Las Palmas, Spain. bernardinoclavo@terra.es
OBJECT: In previous studies the authors have shown potential increases in
locoregional blood flow and oxygenation in tumors by using electrical
cervical spinal cord stimulation (SCS). In the present report they
demonstrate the effect of cervical SCS on brain tumor metabolism, as
assessed using [18F]fluorodeoxyglucose-positron emission tomography (FDG-PET).
METHODS: Cervical devices were inserted in 11 patients who had high-grade
gliomas, six of which had recurred. While the SCS device was deactivated,
each patient underwent an initial FDG-PET study to clarify the clinical
status. A second FDG-PET study was performed later the same day while the
stimulation device was activated to determine the effect of cervical SCS on
glucose metabolism. All 11 patients were invaluable for this PET study.
Basal glucose metabolism was higher in the tumor than in the peritumoral
areas (p = 0.048). There was a significant increase in glucose uptake during
cervical SCS in both the tumor (p = 0.035) and the peritumoral (p = 0.001)
areas, with measured increases of 43 and 38%, respectively. The estimated
potential maximal residual activity of the first FDG dose's contribution to
the activity on the second scan was 18.5 +/- 1% or less. CONCLUSIONS: This
PET study is the first in which is described the effect of cervical SCS on
glucose metabolism in brain tumors and supports previous study data
indicating a modification of locoregional blood flow and oxygenation by
cervical SCS. These results open up new approaches to modifying the effect
of radiochemotherapy in the treatment of malignant brain tumors.
PMID: 16619657 [PubMed - indexed for MEDLINE]>>>
-
| 13: J Neurosurg. 2006 Mar;104(3):360-8. |
|
Effectiveness of neuronavigation in resecting solitary
intracerebral contrast-enhancing tumors: a randomized controlled trial.
Willems
PW, Taphoorn
MJ, Burger
H, Berkelbach
van der Sprenkel JW, Tulleken
CA.
Department of Neurosurgery, University Medical Center Utrecht, The
Netherlands. p.willems@neuro.azu.nl
OBJECT: The goal of this study was to assess the impact of neuronavigation
on the cytoreductive treatment of solitary contrast-enhancing intracerebral
tumors and outcomes of this treatment in cases in which neuronavigation was
preoperatively judged to be redundant. METHODS: The authors conducted a
prospective randomized study in which 45 patients, each harboring a solitary
contrast-enhancing intracerebral tumor, were randomized for surgery with or
without neuronavigation. Peri- and postoperative parameters under
investigation included the following: duration of the procedure; surgeon's
estimate of the usefulness of neuronavigation; quantification of the extent
of resection, determined using magnetic resonance imaging; and the
postoperative course, as evaluated by neurological examinations, the
patient's quality-of-life self-assessment, application of the Barthel index
and the Karnofsky Performance Scale score, and the patient's time of death.
The mean amount of residual tumor tissue was 28.9% for standard surgery (SS)
and 13.8% for surgery involving neuronavigation (SN). The corresponding mean
amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%,
respectively. These differences were not significant. Gross-total removal (GTR)
was achieved in five patients who underwent SS and in three who underwent SN.
Median survival was significantly shorter in the SN group (5.6 months
compared with 9 months, unadjusted hazard ratio = 1.6); however, this
difference may be attributable to the coincidental early death of three
patients in the SN group. No discernible important effect on the patients'
3-month postoperative course was identified. CONCLUSIONS: There is no
rationale for the routine use of neuronavigation to improve the extent of
tumor resection and prognosis in patients harboring a solitary enhancing
intracerebral lesion when neuronavigation is not already deemed advantageous
because of the size or location of the lesion.
Publication Types:
- Randomized
Controlled Trial
PMID: 16572647 [PubMed - indexed for MEDLINE]>>>
-
| 14: Neuro-oncol.
2006 Apr;8(2):189-93. Epub 2006 Mar 13. |
|
-
A phase 2 trial of irinotecan (CPT-11) in patients with
recurrent malignant glioma: a North American Brain Tumor Consortium study.
Prados
MD, Lamborn
K, Yung
WK, Jaeckle
K, Robins
HI, Mehta
M, Fine
HA, Wen
PY, Cloughesy
T, Chang
S, Nicholas
MK, Schiff
D, Greenberg
H, Junck
L, Fink
K, Hess
K, Kuhn
J; North
American Brain Tumor Consortium.
University of California, San Francisco, San Francisco, California
94143-0372, USA. pradosm@neurosurg.ucsf.edu
The purpose of this study was to determine the response to CPT-11
administered every three weeks to adults with progressive malignant glioma,
treated with or without enzyme-inducing antiepileptic drug (EIAED) therapy,
at the recommended phase 2 dose determined from a previous phase 1 study.
Adult patients age 18 or older with a KPS of 60 or higher who had measurable
recurrent grade III anaplastic glioma (AG) or grade IV glioblastoma
multiforme (GBM) were eligible. No more than one prior chemotherapy was
allowed, either as adjuvant therapy or for recurrent disease. The CPT-11
dose was 350 mg/m(2) i.v. every three weeks in patients not on EIAED and 750
mg/m(2) in patients on EIAED therapy. Patients with stable or responding
disease could be treated until tumor progression or a total of 12 months of
therapy. The primary end point of the study was to determine whether CPT-11
could significantly delay tumor progression, using the rate of six-month
progression-free survival (PFS-6). The trial was sized to be able to
discriminate between a 15% and 35% rate for the GBM group alone and between
a 20% and 40% rate for the entire cohort. There were 51 eligible patients,
including 38 GBM and 13 AG patients, enrolled. The median age was 52 and 42
years, respectively. PFS-6 for the entire cohort was 17.6%. PFS-6 was 15.7%
(95% confidence interval [CI], 0.07-0.31) for the GBM patients and 23% (95%
CI, 0.07-0.52) for AG patients. Toxicity for the group included diarrhea and
myelosuppression. We conclude that the recommended phase 2 dose of CPT-11
for patients with or without EIAED was ineffective on this schedule, in this
patient population.
Publication Types:
PMID: 16533878 [PubMed - indexed for MEDLINE]>>>
-
| 15: Neuro-oncol.
2006 Apr;8(2):183-8. Epub 2006 Mar 8. |
|
-
High-dose chemotherapy with stem cell rescue as initial
therapy for anaplastic oligodendroglioma: long-term follow-up.
Abrey
LE, Childs
BH, Paleologos
N, Kaminer
L, Rosenfeld
S, Salzman
D, Finlay
JL, Gardner
S, Peterson
K, Hu
W, Swinnen
L, Bayer
R, Forsyth
P, Stewart
D, Smith
AM, Macdonald
DR, Weaver
S, Ramsay
DA, Nimer
SD, DeAngelis
LM, Cairncross
JG.
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York,
NY 10021, USA. abreyl@mskcc.org
We previously reported a phase 2 trial of 69 patients with newly diagnosed
anaplastic or aggressive oligodendroglioma who were treated with intensive
procarbazine, CCNU (lomustine), and vincristine (PCV) followed by high-dose
thiotepa with autologous stem cell rescue. This report summarizes the
long-term follow-up of the cohort of 39 patients who received high-dose
thiotepa with autologous stem cell support. Thirty-nine patients with a
median age of 43 (range, 18-67) and a median KPS of 100 (range, 70-100) were
treated. Surviving patients now have a median follow-up of 80.5 months
(range, 44-142). The median progression-free survival is 78 months, and
median overall survival has not been reached. Eighteen patients (46%) have
relapsed. Neither histology nor prior low-grade oligodendroglioma correlated
with risk of relapse. Persistent nonenhancing tumor at transplant was
identified in our initial report as a significant risk factor for relapse;
however, long-term follow-up has not confirmed this finding. Long-term
neurotoxicity has developed only in those patients whose disease relapsed
and required additional therapy; no patient in continuous remission has
developed a delayed neurologic injury. This treatment strategy affords
long-term disease control to a subset of patients with newly diagnosed
anaplastic oligodendroglioma without evidence of delayed neurotoxicity or
myelodysplasia.
Publication Types:
- Clinical
Trial, Phase II
- Multicenter
Study
PMID: 16524945 [PubMed - indexed for MEDLINE]>>>
-
| 16: Eur
J Cancer. 2006 May;42(7):917-21. Epub 2006 Mar 6. |
|
-
Head injury and brain tumours in adults: A case-control
study in Rio de Janeiro, Brazil.
Monteiro
GT, Pereira
RA, Koifman
RJ, Koifman
S.
Department of Epidemiology, National School of Public Health, FIOCRUZ,
Oswaldo Cruz Foundation, Rua Leopoldo Bulhoes, 1480 sala 812, Manguinhos,
CEP: 21.041-210, Rio de Janeiro, Brazil. gtorres@cremerj.com.br
A hospital-based case-control study exploring the association between
selected risk factors and head injury in adults, brain trauma included, was
carried out in Greater Metropolitan Rio de Janeiro, Brazil. Cases included
adults diagnosed with primary brain tumours (n = 231). Controls were matched
for gender and age among in-patients hospitalized for various conditions
unrelated to brain cancer (n = 261) identified in the same hospitals where
cases were enrolled. Risk of having experienced head injury was more
frequent among cases (46%) than controls (36%) (OR(adj) = 1.49; 95% CI =
1.03-2.15). A dose-response effect was observed according to the number of
head injuries, and a statistically borderline association was observed for
meningioma (OR(adj) = 1.63; 95% CI = 0.96-2.75). Although recall bias cannot
be ruled out, our results suggest an association between prior head injury
and the development of brain tumours in adults.
Publication Types:
PMID: 16517153 [PubMed - indexed for MEDLINE]>>>
-
|
Volume 5, Number 26 - 26 June 2006